Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recordati’s Orphan Europe gets Graspa rights from Erytech

Executive Summary

Orphan Europe, the rare disease division of Recordati Industria Chimica & Farmaceutica SPA, has licensed European commercialization rights to the leukemia candidate Graspa (L-asparaginase) from Erytech Pharma SA (mainly cancer therapeutics). Erytech is in charge of remaining development and manufacturing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register